Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.35 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP1 | P63208 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23900328 | 0.87 | GAA (0.41) | GAAEPHX2DDB1CRBNNFKB1 | |
| SCHEMBL30314386 | 0.87 | GAA (0.41) | GAAEPHX2DDB1CRBNNFKB1 | |
| SCHEMBL29014262 | 0.87 | GAA (0.41) | GAAEPHX2DDB1CRBNNFKB1 | |
| SCHEMBL30160156 | 0.82 | EPHX2 (0.46) | GAAEPHX2DDB1CRBNRIPK1 | |
| SCHEMBL23555100 | 0.82 | EPHX2 (0.46) | GAAEPHX2DDB1CRBNRIPK1 | |
| SCHEMBL19523036 | 0.77 | GAA (0.44) | GAAEPHX2DDB1CRBNNFKB1 | |
| SCHEMBL25875347 | 0.77 | SCN9A (0.46) | RIPK1SCN9ABACE1 | |
| SCHEMBL5640963 | 0.77 | EPHX2 (0.56) | GAAEPHX2RIPK1 | |
| SCHEMBL1269023 | 0.77 | EPHX2 (0.56) | GAAEPHX2RIPK1 | |
| SCHEMBL1269022 | 0.77 | EPHX2 (0.56) | GAAEPHX2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230227469-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043629-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | GAA 1283/4885EPHX2 3850/4885DDB1 511/4885 |
| US-20230227469-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | GAA 1283/4885EPHX2 3850/4885DDB1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.